Assembly Biosciences Inc (ASMB) Q3 2015 10-Q Quarterly Earnings

Short answer

Assembly Biosciences Inc (ASMB) filed its Q3 2015 10-Q quarterly report on Nov 9, 2015 for the quarter ended Sep 30, 2015.

AI summary of MD&A and risk factor updates

No product revenue in Q3 2015, unchanged from Q3 2014
Operating loss figures not stated; R&D expense $4.48M vs $1.75M, up 157% YoY
HBV program strongest spending growth, R&D increase $1.49M; Microbiome increase $1.65M
Operating cash use $13.24M; investing cash use $61.02M for marketable securities
Equity financing generated $81.0M net proceeds; cash expected to fund operations at least twelve months

No material risk-factor changes disclosed, with Item 1A providing no substantive risk text
Regulatory risk: no FDA-approved products, leaving commercialization dependent on future regulatory approval
Operational risk: HBV and microbiome programs require increasing preclinical and clinical expenditures
Financial risk: $13,242,134 operating cash use during nine months ended September 30, 2015
Funding risk: existing cash expected to cover operating requirements for at least twelve months, but additional financing needed thereafter

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.